Literature DB >> 24384015

RAS in FGF23: another piece in the puzzle.

Diana Ovejero1, Michael T Collins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24384015      PMCID： PMC3879671          DOI： 10.1210/jc.2013-4290

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  22 in total

1.  FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis.

Authors:  Takashi Shimada; Hisashi Hasegawa; Yuji Yamazaki; Takanori Muto; Rieko Hino; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  J Bone Miner Res       Date:  2003-12-29       Impact factor: 6.741

2.  Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia.

Authors:  Young H Lim; Diana Ovejero; Jeffrey S Sugarman; Cynthia M C Deklotz; Ann Maruri; Lawrence F Eichenfield; Patrick K Kelley; Harald Jüppner; Michael Gottschalk; Cynthia J Tifft; Rachel I Gafni; Alison M Boyce; Edward W Cowen; Nisan Bhattacharyya; Lori C Guthrie; William A Gahl; Gretchen Golas; Erin C Loring; John D Overton; Shrikant M Mane; Richard P Lifton; Moise L Levy; Michael T Collins; Keith A Choate
Journal:  Hum Mol Genet       Date:  2013-09-04       Impact factor: 6.150

3.  Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect.

Authors:  T Nesbitt; T M Coffman; R Griffiths; M K Drezner
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

5.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

6.  FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa.

Authors:  Takashi Shimada; Itaru Urakawa; Yuji Yamazaki; Hisashi Hasegawa; Rieko Hino; Takashi Yoneya; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Biochem Biophys Res Commun       Date:  2004-02-06       Impact factor: 3.575

7.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis.

Authors:  Orit Topaz; Daniel L Shurman; Reuven Bergman; Margarita Indelman; Paulina Ratajczak; Mordechai Mizrachi; Ziad Khamaysi; Doron Behar; Dan Petronius; Vered Friedman; Israel Zelikovic; Sharon Raimer; Arieh Metzker; Gabriele Richard; Eli Sprecher
Journal:  Nat Genet       Date:  2004-05-09       Impact factor: 38.330

8.  Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism.

Authors:  Takashi Shimada; Makoto Kakitani; Yuji Yamazaki; Hisashi Hasegawa; Yasuhiro Takeuchi; Toshiro Fujita; Seiji Fukumoto; Kazuma Tomizuka; Takeyoshi Yamashita
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

9.  Postzygotic HRAS mutation causing both keratinocytic epidermal nevus and thymoma and associated with bone dysplasia and hypophosphatemia due to elevated FGF23.

Authors:  Emily Avitan-Hersh; Sameh Tatur; Margarita Indelman; Vardit Gepstein; Roni Shreter; Dov Hershkovitz; Riva Brick; Reuven Bergman; Dov Tiosano
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

10.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting.

Authors:  Mara Riminucci; Michael T Collins; Neal S Fedarko; Natasha Cherman; Alessandro Corsi; Kenneth E White; Steven Waguespack; Anurag Gupta; Tamara Hannon; Michael J Econs; Paolo Bianco; Pamela Gehron Robey
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.